Communication Dans Un Congrès Année : 2020

Peanut gastrointestinal delivery oral immunotherapy in adolescents: Basophil activation test results of the build-up and maintenance phase of the PITA study

Résumé

Disclosure On behalf to PITA group. Background PITA group has tested a new approach in oral immunotherapy to peanut using sealed capsules of peanut to bypass the upper gastrointestinal tract. This protocol demonstrated clinical and immunological efficacy during the build-up phase. We presented here, the data of BAT during the build-up and the maintenance phase. Method Adolescents aged 12-18 y with peanut allergy proven in a first double-blind Placebo-controlled oral food challenge (DBPCFC) will enter a double-blind placebo-controlled build-up phase. The inclusion step included a DBPCFC and a BAT (#1) to whole extract peanut and Ara h 2. After a successful build-up phase objectived by DBPCFC and BAT (#2), duration of the maintenance phase will be determined by a randomization testing 13 or 37 week and efficacy were determined by DBPCFC and BAT (#3). Results Analysis were performed on 44 patients. BAT results shown a significant decrease of f13-CD63 CDsens, f13-CD63 CDmax and f13-CD63 AUC (p<0.001, p<0.05 and p<0.01, respectively) in peanut treated patient after SIT (#2) in comparison to before SIT (#1) (Build-up phase). In accordance to our previous published result, no significant result were obtained after the build-up phase based on the analysis of Arah2-CD63 CDsens. Regarding to the maintenance phase, patients observing a 13-week maintenance phase had lower f13-CD63 CDsens, f13-CD63 AUC and f13-CD63 CDmax than the group observing a 37-week maintenance phase, which is correlated with DBPCFC #3 results and clinical data. Also, compared to BAT results after the build-up phase (#2), f13-CD63 BAT results (CDsens, CDmax and AUC) after the maintenance phase (#3) suggest that patients observing a 13-week maintenance phase have a higher level of SIT-induced protection than patients observing a 37-week maintenance period who tend to lose their SIT-induced protection. No significant result were obtained based on the analysis of Ara h2 CDsens, Ara h2 AUC and Ara h2 CDmax (CD63 and CD203). Conclusion Our study confirms that whole extract peanut BAT (CDsens, CDmax and AUC) is associated to eliciting dose of peanut in allergic patients and remains a safe and a non-invasive tool to assess the tolerance of a patient to given amount of an allergen and could thus allow the monitoring of the SIT protocol, including during the maintenance phase.

Dates et versions

hal-04885592 , version 1 (14-01-2025)

Identifiants

Citer

Benjamin Bonnet, Maud Godignon, Elodie Michaud, Bruno Pereira, Emmanuelle Rochette, et al.. Peanut gastrointestinal delivery oral immunotherapy in adolescents: Basophil activation test results of the build-up and maintenance phase of the PITA study. World Allergy Congress, Sep 2019, Lyon, France. pp.100336, ⟨10.1016/j.waojou.2020.100336⟩. ⟨hal-04885592⟩
89 Consultations
0 Téléchargements

Altmetric

Partager

  • More